

28th Annual South Florida Residency Seminar

Another Year in Miami!

January 20 and 21, 2024

16 total Live Hours (20-1117238): 14 hours Continuing Education Credit for General Continuing Education – GCE/TCE OR 12hr RCE + 2hr GCE for Consultant Recertification – RCE PLUS 2hr Validating Controlled Substances (20-1117178) For Pharmacists and Technicians

Live & Virtual Meeting

The Dade County Pharmacy Association is proudly celebrating the 28th year presenting the Residency Program. This year, we will have two tracks each day: Track 1 will be the Consultant Pharmacist Track (12hr RCE plus 2hr GCE) and Track 2 will be General CE for Pharmacists and Technicians. This year we are also offering the required Validating Controlled Substances the required 2-hour general CE course.

Our presenters are the post-graduate Pharmacy Residents who are completing their training at South Florida facilities including Baptist Hospital of Miami (BHM), Baptist Hospital of Boca Raton (BHB), Baptist Hospital of Homestead (BHH), Baptist Hospital of West Kendall (BHWK), Baptist Hospital of South Miami (BHSM), Jackson Memorial Hospital (JMH), Larkin Health (LH), Miami VA Healthcare System(MVA), Mount Sinai Medical Center (MSMC), Nicklaus Children's Hospital (NCH), Nova Southeastern University (NSU), and University of Miami (UM), Walgreens/NSU (WNSU), Thanks to the residents and their preceptors for sharing in their experiences.

NOTE: This course is Florida Accredited program NOT an ACPE program. Florida Credits are posted to CE Broker only.



Location: Either in the comfort of your home via virtual conference or LIVE at the Double Tree Mart Plaza by Hilton Hotel (711 NW 72nd Ave, Miami Fl)

Cancellation Policy:

If cancellation is made in writing 30 days prior to the program a refund will be made less a \$15 service fee. If written cancellation is made 29-10 days prior to the program a refund will be made, less a \$25 service fee. No refunds for requests will be honored if received after 4pm, 9 days prior to the program.

Virtual ZOOM information: You can join through a desktop computer, laptop, iPad, tablet, or smart phone. A strong internet connection is recommended. You will be provided with full instructions on how to pre-register on Zoom along with the process to join the meeting and evaluate the program and speakers. *There is an additional administrative charge for this attendance option*.

On-Line Downloadable Resources:

Goals and Objectives with Full Handouts

TRACK 1 - Saturday, January 20, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon 8:00-10:00am 20-1117178 2hr Validating Controlled Substances Prescriptions. Unicus the rationale and importance of ensuring access to controlled substances (CS) to patients as validly prescribed by their provider. Review Florida's Prescription Drug Monitoring Program's Database (PDMP) and its role in validating CS prescriptions. Conduct a clinical assessment of the patient's need for CS prescribed for: appropriate therapeutic value, Drug/drug interaction, dosing guidelines 4. Identify methods for detection and validating CS prescriptions to include legitimate medical purposes. 5. Discuss the laws and regulations related to the prescribing and dispensing of CS prescriptions to include: Partial filling, Emergency filling 6. Review pharmacist-initiated patient counseling for CS prescriptions including: adverse effects/side effects; potential drug/drug interactions; available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology Updates in Oncology, Katherine Fernandez PharmD & Ryan Falcon PharmD (BHM) 1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BITE technology 5. Analyze the potential place in therapy for BITE technology 6. Examine trials utilizing BITE technology 7. Analyze the potential place in therapy for BITE technology 8. Evaluate clinical pearls and place in therapy for BITE technology 9. Recognize the potential side effects of CAR T-cell therapy. 9. Recognize the potential side effects of CAR T-cell therapy. 9. Recognize the potential side effects of CAR T-cell therapy. 9. Lench & Stretch Break 1. Disease Manag	20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon 8:00-10:00am 20-117178 2hr Validating Controlled Substances Prescriptions. Veronica Blasky-Lopez PharmD & Nayvel Cairo PharmD (BHWK) 1. Discuss the rationale and importance of ensuring access to controlled substances (CS) to patients as validly prescribed by their provider. 2. Review Florida's Prescription Drug Monitoring Program's Database (PDMP) and its role in validating CS prescriptions. 3. Conduct a clinical assessment of the patient's need for CS prescribed for: appropriate therapeutic value, Drug/drug interaction, dosing guidelines 4. Identify methods for detection and validating CS prescriptions to include legitimate medical purposes. 5. Discuss the laws and regulations related to the prescribing and dispensing of CS prescriptions to include: Partial filling, Emergency filling 6. Review pharmacist-initiated patient counseling for CS prescriptions including: adverse effects/side effects; potential drug/drug interactions; available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology 10:00-12:00am 2hr 1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BTE technology 5. Analyze the potential place in therapy for novel oncolytics 4. Define BTE technology CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the PDA approved CAR T-Cell therapy.
8:00-10:00am 20-1117178 2hr Alidating Controlled Substances Prescriptions. Veronica Blasky-Lopez PharmD & Nayvel Cairo PharmD (BHWK) 1. Discuss the rationale and importance of ensuring access to controlled substances (CS) to patients as validly prescribed by their provider. 2. Review Florida's Prescription Drug Monitoring Program's Database (PDMP) and its role in validating CS prescriptions. 3. Conduct a clinical assessment of the patient's need for CS prescribed for: appropriate therapeutic value, Drug/drug interaction, dosing guidelines 4. Identify methods for detection and validating CS prescriptions to include legitimate medical purposes. 5. Discuss the laws and regulations related to the prescribing and dispensing of CS prescriptions to include: Partial filling, Emergency filling 6. Review pharmacist-initiated patient counseling for CS prescriptions including: adverse effects/side effects; potential drug/drug interactions; available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology 10:00-12:00am 2hr 1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytics agents 3. Evaluate clinical pearls and place in therapy for BITE technology 5. Analyze the potential place in therapy for BITE technology 6. Examine trials utilizing BITE technology 7. Analyze the potential place in therapy for BITE technology 8. Analyze the potential place in therapy for BITE technology 9. Recognize the process of CAR T-cell therapy. 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Lidentify the FDA approved CAR T-cell therapy. 4. Lidentify the FDA approved CAR T-cell therapy. 5. Disease Management with a Focus on Infectious Diseases	8:00-10:00am 20-111778 2hr 2hr 2hr 2hr 2hr 2hr 2hr 2hr
Validating Controlled Substances Prescriptions. Veronica Blasky-Lopez PharmD & Nayvel Cairo PharmD (BHWK) 1. Discuss the rationale and importance of ensuring access to controlled substances (CS) to patients as validly prescribed by their provider. 2. Review Florida's Prescription Drug Monitoring Program's Database (PDMP) and its role in validating CS prescriptions. 3. Conduct a clinical assessment of the patient's need for CS prescribed for: appropriate therapeutic value, Drug/drug interaction, dosing guidelines 4. Identify methods for detection and validating CS prescriptions to include legitimate medical purposes. 5. Discuss the laws and regulations related to the prescribing and dispensing of CS prescriptions to include: Partial filling, Emergency filling 6. Review pharmacist-initiated patient counseling for CS prescriptions including: adverse effects/side effects; potential drug/drug interactions; available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose	Validating Controlled Substances Prescriptions. Veronica Blasky-Lopez PharmD & Nayvel Cairo PharmD (BHWK)
2. Discuss the rationale and importance of ensuring access to controlled substances (CS) to patients as validly prescribed by their provider. 2. Review Florida's Prescription Drug Monitoring Program's Database (PDMP) and its role in validating CS prescriptions. 3. Conduct a clinical assessment of the patient's need for CS prescribed for: appropriate therapeutic value, Drug/drug interaction, dosing guidelines 4. Identify methods for detection and validating CS prescriptions to include legitimate medical purposes. 5. Discuss the laws and regulations related to the prescribing and dispensing of CS prescriptions to include: Partial filling, Emergency filling 6. Review pharmacist-initiated patient counseling for CS prescriptions including: adverse effects/side effects; potential drug/drug interactions; available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology 1:000-12:00am 2hr 1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BITE technology 5. Analyze the potential place in therapy for BITE technology 6. Examine trials utilizing BITE technology 6. Examine trials utilizing BITE technology CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapies. 12:00pm-1:00pm Lunch & Stretch Break Disease Management with a Focus on Infectious Diseases	2hr 1. Discuss the rationale and importance of ensuring access to controlled substances (CS) to patients as validly prescribed by their provider. 2. Review Florida's Prescription Drug Monitoring Program's Database (PDMP) and its role in validating CS prescriptions. 3. Conduct a clinical assessment of the patient's need for CS prescribed for: appropriate therapeutic value, Drug/drug interaction, dosing quidelines 4. Identify methods for detection and validating CS prescriptions to include legitimate medical purposes. 5. Discuss the laws and regulations related to the prescribing and dispensing of CS prescriptions to include: Partial filling, Emergency filling 6. Review pharmacist-initiated patient counseling for CS prescriptions including: adverse effects/side effects; potential drug/drug interactions, available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology 10:00-12:00am 2hr 1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BITE technology 5. Examine trials utilizing BITE technology 6. Examine trials utilizing BITE technology 6. Examine trials utilizing BITE technology 7. Describe the process of CART-cell therapy. 8. Recognize the potential side effects of CAR T-cell therapy. 9. Recognize the potential side effects of CAR T-cell therapy. 1. Background: Discuss background and pathophysiology of HIV 2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms
their provider. 2. Review Florida's Prescription Drug Monitoring Program's Database (PDMP) and its role in validating CS prescriptions. 3. Conduct a clinical assessment of the patient's need for CS prescribed for: appropriate therapeutic value, Drug/drug interaction, dosing guidelines 4. Identify methods for detection and validating CS prescriptions to include legitimate medical purposes. 5. Discuss the laws and regulations related to the prescribing and dispensing of CS prescriptions to include: Partial filling, Emergency filling 6. Review pharmacist-initiated patient counseling for CS prescriptions including: adverse effects/side effects; potential drug/drug interactions; available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology 10:00-12:00am 2hr 1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BiTE technology 5. Analyze the potential place in therapy for BiTE technology 6. Examine trials utilizing BiTE technology 7. Describe the process of CAR T-cell therapy. 7. Recognize the potential side effects of CAR T-cell therapy. 7. Recognize the potential side effects of CAR T-cell therapy. 7. Recognize the potential side effects of CAR T-cell therapy. 8. Recognize the potential side effects of CAR T-cell therapy. 9. Recognize the potential side effects of CAR T-cell therapies. 1. Unchas Stretch Break Disease Management with a Focus on Infectious Diseases	heir provider. 2. Review Florida's Prescription Drug Monitoring Program's Database (PDMP) and its role in validating CS prescriptions. 3. Conduct a clinical assessment of the patient's need for CS prescribed for: appropriate therapeutic value, Drug/drug interaction, dosing guidelines 4. Identify methods for detection and validating CS prescriptions to include legitimate medical purposes. 5. Discuss the laws and regulations related to the prescribing and dispensing of CS prescriptions to include: Partial filling, Emergency filling 6. Review pharmacist-initiated patient counseling for CS prescriptions including: adverse effects/side effects; potential drug/drug interactions; available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal. 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology 10:00-12:00am 2hr 10:00
2. Review Florida's Prescription Drug Monitoring Program's Database (PDMP) and its role in validating CS prescriptions. 3. Conduct a clinical assessment of the patient's need for CS prescribed for: appropriate therapeutic value, Drug/drug interaction, dosing guidelines 4. Identify methods for detection and validating CS prescriptions to include legitimate medical purposes. 5. Discuss the laws and regulations related to the prescribing and dispensing of CS prescriptions to include: Partial filling, Emergency filling 6. Review pharmacist-initiated patient counseling for CS prescriptions including: adverse effects/side effects; potential drug/drug interactions; available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology 10:00-12:00am 2hr 10:00-12:00a	a. Review Florida's Prescription Drug Monitoring Program's Database (PDMP) and its role in validating CS prescriptions. 3. Conduct a clinical assessment of the patient's need for CS prescribed for: appropriate therapeutic value, Drug/drug interaction, dosing guidelines 4. Identify methods for detection and validating CS prescriptions to include legitimate medical purposes. 5. Discuss the laws and regulations related to the prescribing and dispensing of CS prescriptions to include: Partial filling, Emergency filling 6. Review pharmadist-initiated patient counseling for CS prescriptions including: adverse effects/side effects; potential drug/drug interactions; available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology 10:00-12:00am 2hr 1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pears and place in therapy for novel oncolytics 4. Define BITE technology 5. Analyze the potential place in therapy for novel oncolytics 4. Define BITE technology 6. Examine trials utilizing BITE technology 6. Examine trials utilizing BITE technology 7. Recognize the potential side effects of CAR T-cell therapy. 7. Recognize the potential side effects of CAR T-cell therapy. 8. Recognize the potential side effects of CAR T-cell therapy. 9. Recognize the potential side effects of CAR T-cell therapy. 9. Recognize the potential side effects of CAR T-cell therapies. 9. Recognize the potential side effects of CAR T-cell therapies. 9. Recognize the potential side effects of CAR T-cell therapies. 9. Recognize the potential side effects of CAR T-cell therapies. 9. Recognize the potential side effects of CAR T-cell therapies. 9. Recognize the potential side effects of CAR T-cell therapies. 9. Recognize the potential side effects of CAR T-cell therapies
Interaction, dosing guidelines 4. Identify methods for detection and validating CS prescriptions to include legitimate medical purposes. 5. Discuss the laws and regulations related to the prescribing and dispensing of CS prescriptions to include: Partial filling, Emergency filling 6. Review pharmacist-initiated patient counseling for CS prescriptions including: adverse effects/side effects; potential drug/drug interactions; available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose 10:00-12:00am 2hr 1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BiTE technology 5. Analyze the potential place in therapy for BITE technology 6. Examine trials utilizing BiTE technology CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapies. 12:00pm-1:00pm 1. Unch & Stretch Break 1. Disease Management with a Focus on Infectious Diseases 1. Disease Management with a Focus on Infectious Diseases 1. Disease Management with a Focus on Infectious Diseases 1. Disease Management with a Focus on Infectious Diseases 1. Disease Management with a Focus on Infectious Diseases 1. Disease Management with a Focus on Infectious Diseases 1. Disease Management with a Focus on Infectious Diseases 1. Disease Management with a Focus on Infectious Disease 1. Disease Management with a Focus on Infectious Disease 1. Disease Management with a Focus on Infectious Disease 1. Disease Management with a Focus on Infectious Disease 1. Disease Management with a Focus on Infectious Disease 1. Disease Management with a Focus on Infectious Disease	interaction, dosing guidelines 4. Identify methods for detection and validating CS prescriptions to include legitimate medical purposes. 5. Discuss the laws and regulations related to the prescribing and dispensing of CS prescriptions to include: Partial filling, Emergency filling 6. Review pharmacist-initiated patient counseling for CS prescriptions including: adverse effects; side effects; potential drug/drug interactions; available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology 10:00-12:00am 2hr 1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BITE technology 5. Analyze the potential place in therapy for novel oncolytics 4. Define BITE technology 6. Examine trials utilizing BITE technology 6. Examine trials utilizing BITE technology 7. Recognize the potential side effects of CAR T-cell therapy. 7. Recognize the potential side effects of CAR T-cell therapy. 8. Identify the FDA approved CAR T-cell therapy. 9. Recognize the potential side effects of CAR T-cell therapy. 9. Identify the FDA approved CAR T-cell therapy. 9. Identify the FD
4. Identify methods for detection and validating CS prescriptions to include legitimate medical purposes. 5. Discuss the laws and regulations related to the prescribing and dispensing of CS prescriptions to include: Partial filling, Emergency filling 6. Review pharmacist-initiated patient counseling for CS prescriptions including: adverse effects/side effects; potential drug/drug interactions; available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology 10:00-12:00am 2hr 1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BiTE technology 5. Analyze the potential place in therapy for BiTE technology 6. Examine trials utilizing BiTE technology 7. Describe the process of CAR T-cell therapy. 7. Recognize the potential side effects of CAR T-cell therapy. 7. Recognize the potential side effects of CAR T-cell therapy. 7. Recognize the potential side effects of CAR T-cell therapy. 7. Recognize the potential side effects of CAR T-cell therapy. 7. Recognize the potential side effects of CAR T-cell therapy. 7. Recognize the potential side effects of CAR T-cell therapy. 7. Recognize the potential side effects of CAR T-cell therapy. 7. Recognize the potential side effects of CAR T-cell therapy. 8. Identify the FDA approved CAR T-Cell therapies. Disease Management with a Focus on Infectious Diseases	A lidentify methods for detection and validating CS prescriptions to include legitimate medical purposes. S. Discuss the laws and regulations related to the prescribing and dispensing of CS prescriptions to include: Partial filling, Emergency filling
Emergency filling 6. Review pharmacist-initiated patient counseling for CS prescriptions including: adverse effects/side effects; potential drug/drug interactions; available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology 10:00-12:00am 2hr Updates In Oncology. Katherine Fernandez PharmD & Ryan Falcon PharmD (BHM) 1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BITE technology 5. Analyze the potential place in therapy for BITE technology 6. Examine trials utilizing BITE technology 7. Describe the process of CAR T-cell therapy. 9. Recognize the potential side effects of CAR T-cell therapy. 9. Recognize the potential side effects of CAR T-cell therapy. 9. Recognize the potential side effects of CAR T-cell therapy. 9. Identify the FDA approved CAR T-Cell therapies. Disease Management with a Focus on Infectious Diseases	Emergency filling 6. Review pharmacist-initiated patient counseling for CS prescriptions including: adverse effects/side effects; potential drug/drug interactions, available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology 10:00-12:00am 2hr 1. Identify newly approved oncolytic agents 2. Explain the clinical pearls and place in therapy for novel oncolytics 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BITE technology 5. Analyze the potential place in therapy for BITE technology 6. Examine trials utilizing BITE technology 7. Explain the clinical pearls and place in therapy for BITE technology 8. Examine trials utilizing BITE technology 9. Exemple the process of CAR T-cell therapy. 9. Recognize the potential place in therapy for BITE technology 9. Examine trials utilizing BITE technology 9. Examine trials utilizing BITE technology 9. Exemple the process of CAR T-cell therapy. 9. Recognize the potential side effects; of CAR T-cell therapy. 9. Recognize the potential side effects of CAR T-cell therapy. 9. Recognize the potential side effects of CAR T-cell therapy. 9. Recognize the potential side effects of CAR T-cell therapy. 9. Recognize the potential side effects of CAR T-cell therapy. 9. Recognize the potential side effects of CAR T-cell therapy. 9. Recognize the potential side effects of CAR T-cell therapy. 9. Lunch & Stretch Break Disease Management with a Focus on Infectious Diseases Disease Management with a Focus on I
6. Review pharmacist-initiated patient counseling for CS prescriptions including: adverse effects/side effects; potential drug/drug interactions; available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology 10:00-12:00am 2hr Updates In Oncology. Katherine Fernandez PharmD & Ryan Falcon PharmD (BHM) Identify newly approved oncolytic agents Explain the clinical trials leading to approval of oncolytic agents Sevaluate clinical trials leading to approval of oncolytics Define BiTE technology Sevaluate clinical pearls and place in therapy for novel oncolytics Define BiTE technology CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. Recognize the potential side effects of CAR T-cell therapy. Recognize the potential side effects of CAR T-cell therapy. Recognize the potential side effects of CAR T-cell therapy. Recognize the potential side effects of CAR T-cell therapy. Carrow Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. Recognize the potential side effects of CAR T-cell therapy. Recognize the potential side effects of CAR T-cell therapy. Carrow Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. Carrow Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. Carrow Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. Carrow Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. Carrow Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. Carrow Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. Carrow Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. Carrow Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. Describe the process of CAR T-cell therapy. Carrow Barnhart PharmD (BHM)	6. Review pharmacist-initiated patient counseling for CS prescriptions including: adverse effects/side effects; potential drug/drug interactions; available treatment resources for opioid dependence, addiction, misuse, or abuse; proper drug storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology Updates In Oncology. Katherine Fernandez PharmD & Ryan Falcon PharmD (BHM) 1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BITE technology 5. Analyze the potential place in therapy for BITE technology 6. Examine trials utilizing BITE technology CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapy. 3. Identify the FDA approved CAR T-Cell therapy. 4. Disease Management with a Focus on Infectious Diseases Disease Management of Pharmacologic Therapies. Andy Fernandez PharmD (NSU) 1. Background: Discuss background and pathophysiology of HIV 2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 3. Summarize pha
storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology 10:00-12:00am 2hr Updates In Oncology. Katherine Fernandez PharmD & Ryan Falcon PharmD (BHM) I. Identify newly approved oncolytic agents Explain the clinical trials leading to approval of oncolytic agents Evaluate clinical pearls and place in therapy for novel oncolytics Define BiTE technology Analyze the potential place in therapy for BiTE technology Examine trials utilizing BiTE technology CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. Recognize the potential side effects of CAR T-cell therapy. Car T-cell therapy. Identify the FDA approved CAR T-Cell therapies. Updates In Oncology. Katherine Fernandez PharmD & Ryan Falcon PharmD (BHM) Describe HE potential place in therapy for novel oncolytic agents CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) Describe the process of CAR T-cell therapy. Describe the process of CAR T-cell therapy	storage conditions, security, and disposal 7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology 10:00-12:00am 2hr 1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BiTE technology 5. Analyze the potential place in therapy for BiTE technology 6. Examine trials utilizing BiTE technology 7. Explain the recognize the potential place in therapy for BiTE technology 8. Analyze the potential place in therapy for BiTE technology 9. CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-cell therapy. 5. Identify the FDA approved CAR T-cell therapy. 5. Identify the FDA approved CAR T-cell therapy. 5. Identify the FDA approved CAR T-cell therapy. 6. Examine trials utilizing biTE technology 6. Examine trials utilizing
7. Explain the use of naloxone for the emergency treatment of suspected drug overdose Disease Management with a Focus on Oncology 10:00-12:00am 2hr 1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BiTE technology 5. Analyze the potential place in therapy for BiTE technology 6. Examine trials utilizing BiTE technology 1:00 - 2:00pm 1hr CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapies. Lunch & Stretch Break Disease Management with a Focus on Infectious Diseases	Disease Management with a Focus on Oncology 10:00-12:00am 2hr Updates In Oncology, Katherine Fernandez PharmD & Ryan Falcon PharmD (BHM) 1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytics agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BITE technology 5. Analyze the potential place in therapy for BITE technology 6. Examine trials utilizing BITE technology 7. Analyze the potential place in therapy for BITE technology 8. Analyze the potential place in therapy for BITE technology 8. Examine trials utilizing BITE technology CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-cell therapy. 3. Identify the FDA approved CAR T-cell therapies. Updates on HIV Pharmacologic Therapies. Andy Fernandez PharmD (NSU) 1. Background: Discuss background and pathophysiology of HIV 2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV
10:00-12:00am 2hr Updates In Oncology. Katherine Fernandez PharmD & Ryan Falcon PharmD (BHM)	10:00-12:00am 2hr Updates In Oncology. Katherine Fernandez PharmD & Ryan Falcon PharmD (BHM) 1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical parls and place in therapy for novel oncolytics 4. Define BiTE technology 5. Analyze the potential place in therapy for BiTE technology 6. Examine trials utilizing BiTE technology 7. Analyze the potential place in therapy for BiTE technology 8. Analyze the potential place in therapy for BiTE technology 8. Analyze the potential place in therapy for BiTE technology 8. Analyze the potential place in therapy for BiTE technology 9. Analyze the potential place in therapy for BiTE technology 1. Describe the process of CAR T-cell therapy. 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapy. 3. Identify the FDA approved CAR T-Cell therapy. 4. Unch & Stretch Break
1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BiTE technology 5. Analyze the potential place in therapy for BiTE technology 6. Examine trials utilizing BiTE technology CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapies. Disease Management with a Focus on Infectious Diseases	1. Identify newly approved oncolytic agents 2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BiTE technology 5. Analyze the potential place in therapy for BiTE technology 6. Examine trials utilizing BiTE technology CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapy. 3. Identify the FDA approved CAR T-Cell therapies. Disease Management with a Focus on Infectious Diseases Updates on HIV Pharmacologic Therapies. Andy Fernandez PharmD (NSU) 1. Background: Discuss background and pathophysiology of HIV 2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections Sunday, January 21, 2024
2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BiTE technology 5. Analyze the potential place in therapy for BiTE technology 6. Examine trials utilizing BiTE technology CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapies. Disease Management with a Focus on Infectious Diseases	2. Explain the clinical trials leading to approval of oncolytic agents 3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BITE technology 5. Analyze the potential place in therapy for BITE technology 6. Examine trials utilizing BITE technology CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapies. 12:00pm-1:00pm Lunch & Stretch Break Disease Management with a Focus on Infectious Diseases Updates on HIV Pharmacologic Therapies. Andy Fernandez PharmD (NSU) 1. Background: Discuss background and pathophysiology of HIV 2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the risk factors and general management of neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections Sunday, January 21, 2024
3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BiTE technology 5. Analyze the potential place in therapy for BiTE technology 6. Examine trials utilizing BiTE technology CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapies. Disease Management with a Focus on Infectious Diseases	3. Evaluate clinical pearls and place in therapy for novel oncolytics 4. Define BTE technology 5. Analyze the potential place in therapy for BITE technology 6. Examine trials utilizing BITE technology 1:00 – 2:00pm 1hr CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapy. 3. Identify the FDA approved CAR T-Cell therapies. Lunch & Stretch Break Disease Management with a Focus on Infectious Diseases 2:00 - 3:00pm 1hr Disease Management with a Focus on Infectious Diseases Updates on HIV Pharmacologic Therapies. Andy Fernandez PharmD (NSU) 1. Background: Discuss background and pathophysiology of HIV 2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections Sunday, January 21, 2024
5. Analyze the potential place in therapy for BiTE technology 6. Examine trials utilizing BiTE technology 1:00 – 2:00pm 1hr CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapies. 12:00pm-1:00pm Lunch & Stretch Break Disease Management with a Focus on Infectious Diseases	5. Analyze the potential place in therapy for BiTE technology 6. Examine trials utilizing BiTE technology 7. CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapies. 12:00pm-1:00pm 1. Lunch & Stretch Break Disease Management with a Focus on Infectious Diseases 2:00 - 3:00pm 1hr Disease Management with a Focus on Infectious Diseases Updates on HIV Pharmacologic Therapies. Andy Fernandez PharmD (NSU) 1. Background: Discuss background and pathophysiology of HIV 2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
6. Examine trials utilizing BiTE technology CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapies. 12:00pm-1:00pm Lunch & Stretch Break Disease Management with a Focus on Infectious Diseases	6. Examine trials utilizing BiTE technology CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapies. 12:00pm-1:00pm Lunch & Stretch Break Disease Management with a Focus on Infectious Diseases 2:00 - 3:00pm 1hr Discuss background and pathophysiology of HIV 2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JIMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1:00 – 2:00pm 1hr CAR T-cell Therapy. Andrew Barnhart PharmD (BHM) 1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapies. 12:00pm-1:00pm Lunch & Stretch Break Disease Management with a Focus on Infectious Diseases	1:00 – 2:00pm 1hr GCE/TCE/RCE 12:00pm-1:00pm Lunch & Stretch Break Disease Management with a Focus on Infectious Diseases 2:00 - 3:00pm 1hr Updates on HIV Pharmacologic Therapies. Andy Fernandez PharmD (NSU) 1. Background: Discuss background and pathophysiology of HIV 2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphillis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapies. 12:00pm-1:00pm	1. Describe the process of CAR T-cell therapy. 2. Recognize the potential side effects of CAR T-cell therapy. 3. Identify the FDA approved CAR T-Cell therapies. 12:00pm-1:00pm
GCE/TCE/RCE 3. Identify the FDA approved CAR T-Cell therapies. 12:00pm-1:00pm Lunch & Stretch Break Disease Management with a Focus on Infectious Diseases	3. Identify the FDA approved CAR T-Cell therapies.
12:00pm-1:00pm Lunch & Stretch Break Disease Management with a Focus on Infectious Diseases	Disease Management with a Focus on Infectious Diseases 2:00 - 3:00pm 1hr Disease Management with a Focus on Infectious Diseases Updates on HIV Pharmacologic Therapies. Andy Fernandez PharmD (NSU) 1. Background: Discuss background and pathophysiology of HIV 2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
<u> </u>	2:00 - 3:00pm 1hr Updates on HIV Pharmacologic Therapies. Andy Fernandez PharmD (NSU) 1. Background: Discuss background and pathophysiology of HIV 2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
	1. Background: Discuss background and pathophysiology of HIV 2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
Opares of the Finance of the Copies and Fernande Property	2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
	3:00-4:00pm 1hr 4:00-5:00pm 1hr 4:00-5:00pm 1hr 6CE/TCE/RCE 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
	1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
	1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
3'UU-4'UUNM INT	2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in	4:00-5:00pm 1hr IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis	PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation	1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez	2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH)	Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections	• • • •
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections	20-111/238 (RCE GCE/TCE) as indicated
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024	
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated	Onsite Attendees will have Full Breakjast at 7am and Lunch at noon.
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon.	Dain Managament
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management	.
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA)
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain 2. Evaluate evidence-based recommendations for a patient specific approach to pain stewardship	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain 2. Evaluate evidence-based recommendations for a patient specific approach to pain stewardship
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain 2. Evaluate evidence-based recommendations for a patient specific approach to pain stewardship 3. Describe responsibilities and opportunities for pharmacist intervention in a comprehensive approach to pain stewardship	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain 2. Evaluate evidence-based recommendations for a patient specific approach to pain stewardship 3. Describe responsibilities and opportunities for pharmacist intervention in a comprehensive approach to pain stewardship
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain 2. Evaluate evidence-based recommendations for a patient specific approach to pain stewardship	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain 2. Evaluate evidence-based recommendations for a patient specific approach to pain stewardship 3. Describe responsibilities and opportunities for pharmacist intervention in a comprehensive approach to pain stewardship
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain 2. Evaluate evidence-based recommendations for a patient specific approach to pain stewardship 3. Describe responsibilities and opportunities for pharmacist intervention in a comprehensive approach to pain stewardship	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain 2. Evaluate evidence-based recommendations for a patient specific approach to pain stewardship 3. Describe responsibilities and opportunities for pharmacist intervention in a comprehensive approach to pain stewardship 4. Describe the influence of pharmacogenetic variations that effect the use and dosing of select analgesics Notice to Consultant Pharmacists – Track 1 must be completed for 12hr consultant credits.
1. Background: Discuss background and pathophysiology of HIV 2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV	IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Background: Discuss background and pathophysiology of HIV	3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024
2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients	3:00-4:00pm 1hr Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients	3:00-4:00pm 1hr Neurosyphilis: A Central Challenge Alejandro Ramirez PharmD (LH)
	3:00-4:00pm 1hr Neurosyphilis: A Central Challenge Alejandro Ramirez PharmD (LH)
	3:00-4:00pm 1hr 4:00-5:00pm 1hr 4:00-5:00pm 1hr 6:00-5:00pm 1hr 6:00-5:00pm 1hr 3:00-4:00pm 1hr 4:00-5:00pm 1hr 5:00pm 1hr 6:00-5:00pm 1hr 6:00-5:00pm 1hr 6:00-5:00pm 1hr 8:00-5:00pm 1hr 8:00-5:00pm 1hr 9:00-5:00pm 1hr 1:00-5:00pm 1hr 9:00-5:00pm 1hr 1:00-5:00pm
	3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
	3:00-4:00pm 1hr Neurosyphilis: A Central Challenge Alejandro Ramirez PharmD (LH)
	3:00-4:00pm 1hr Neurosyphilis: A Central Challenge Alejandro Ramirez PharmD (LH)
	3:00-4:00pm 1hr Neurosyphilis: A Central Challenge Alejandro Ramirez PharmD (LH)
	3:00-4:00pm 1hr Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
	3:00-4:00pm 1hr 4:00-5:00pm 1hr 4:00-5:00pm 1hr 4:00-5:00pm 1hr 6CE/TCE/RCE 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Background: Discuss background and pathophysiology of HIV	3:00-4:00pm 1hr 4:00-5:00pm 1hr 4:00-5:00pm 1hr 4:00-5:00pm 1hr 6CE/TCE/RCE 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Background: Discuss background and pathophysiology of HIV	3:00-4:00pm 1hr 4:00-5:00pm 1hr 4:00-5:00pm 1hr 4:00-5:00pm 1hr 6CE/TCE/RCE 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Background: Discuss background and pathophysiology of HIV	3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Background: Discuss background and pathophysiology of HIV	3:00-4:00pm 1hr 4:00-5:00pm 1hr 4:00-5:00pm 1hr 4:00-5:00pm 1hr 6CE/TCE/RCE 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
Opaces of the Final Harmacologie Therapiest	2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
Opaces of the Final Harmacologie Therapiest	2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
Opares of the Finance of the Control	2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients 3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Background: Discuss background and pathophysiology of HIV	3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
	3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
2. Diagnosis: Evaluate screening and diagnostic work up methods for HIV patients	3:00-4:00pm 1hr Neurosyphilis: A Central Challenge Alejandro Ramirez PharmD (LH)
	3:00-4:00pm 1hr Neurosyphilis: A Central Challenge Alejandro Ramirez PharmD (LH)
	3:00-4:00pm 1hr Neurosyphilis: A Central Challenge Alejandro Ramirez PharmD (LH)
	3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
	3. Treatment: Analyze current and new practice guidelines and treatment/prevention options for HIV Neurosyphilis: A Central Challenge. Alejandro Ramirez PharmD (LH) 1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
	3:00-4:00pm 1hr Neurosyphilis: A Central Challenge Alejandro Ramirez PharmD (LH)
	3:00-4:00pm 1hr Neurosyphilis: A Central Challenge Alejandro Ramirez PharmD (LH)
	1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
	1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
Name and Alle A Cantral Challenge at a series and a series	neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
Neurosyphilis: A Central Challenge. Aleiandro Ramirez PharmD (LH)	2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
3'UU-4'UUNM INT	2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in	3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis	4:00-5:00pm 1hr IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis	4:00-5:00pm 1hr IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis	PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis	PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis	PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis	1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation	1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation	1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez	2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez	2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez	2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH)	GCE/TCE/RCE 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH)	GCE/TCE/RCE 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH)	GCE/TCE/RCE 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria	GCE/TCE/RCE 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria	Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria	Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria	Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections	Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections	•• • •
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections	•• • •
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections	Sunday, January 21, 2024
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections	•• • •
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections	
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections	•• • •
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections	•• • •
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections	•• • •
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections	20-1117238 (RCE GCE/TCE) as Indicated
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections	20-1117236 (NCL GCL) 1CL) as illulcated
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024	Out the Attended on will be one full Bus of freet at 7 and and I work at a con-
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024	OnSite Attendees will have Full Breakfast at 7am and Lunch at noon.
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated	
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management	
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management	
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA)	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA)
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA)	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA)
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections 3. Evaluate current literature available to guide antimicrobial drug use for resistant gram-negative infections Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA) 1. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options for acute and chronic pain
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management 8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA)	8:00-10:00am 2hr What a Pain! - a Comprehensive Review of Pain Management, Stewardship and Pharmacogenomic Considerations. Alexandra Rola PharmD & William Kirsner PharmD (MVA)
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon. Pain Management	
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated OnSite Attendees will have Full Breakfast at 7am and Lunch at noon.	Pain Management
1. Review pathophysiology, epidemiology, clinical presentation, relevant laboratory data, and symptoms assessment in neurosyphilis 2. Discuss the risk factors and general management of neurosyphilis 3. Summarize pharmacologic management based on disease manifestation IDSA Guideline Updates for Antimicrobial Resistant Gram-Negative Infections. Emily Perez PharmD & Valerie Hernandez PharmD (JMH) 1. Discuss the resistance mechanisms in gram-negative bacteria 2. Summarize the 2023 IDSA Guidelines Updates on Treatment of Antimicrobial Resistant Gram-Negative Infections GCE/TCE/RCE Sunday, January 21, 2024 20-1117238 (RCE GCE/TCE) as Indicated	

10:00-11:00am 1hr	Don't Think Too Hard: Managing Headaches and Migraines. Brittany Picardi PharmD (BHB) 1. Differentiate between the different types of headaches based on patient history and presenting signs and symptoms.
	Identify non-pharmacologic and pharmacologic treatment strategies for the treatment and prevention of headache and migraine.
GCE/TCE/ RCE	3. Discuss clinical pearls regarding pharmaceutical treatment options for headache and migraine.
	Update on Critical Care
11:00am -12:00pm 1hr	Stroke. Manar Alkahby PharmD & Eilin Ramos PharmD (BHM)
1111	Discuss the current and updates in stroke pharmacological management Identify agents used for the prevention of stroke in patients with stroke and transient ischemic attack
GCE/TCE/ RCE	3. Describe how pharmacists contribute to fulfilling stroke core measures
12:00pm-1:00pm	Lunch & Stretch Break
1:00 -2:00pm 1hr	Unraveling the Minds Maze: ICU Delirium. Luke Manda PharmD (BHB) & Abraham Felix (BHH)
	1. Determine strategies to minimize delirium through non-pharmacological and supportive treatment
	Analyze appropriate pharmaceutical treatment in patients with ICU delirium Discuss the future of ICU delirium treatment
2:00 -3:00pm 1hr	Venous Thromboembolism: Management in Special Populations. Carina Diaz PharmD & Lesly
, , , , , ,	Rapado PharmD (BHSM)
	Describe the epidemiology and pathophysiology of deep vein thrombosis and pulmonary embolism
	2. Review risk factors, diagnosis, and clinical presentation of venous thromboembolism
	3. Describe guideline-directed medical therapy for prophylaxis and treatment of deep vein thrombosis and pulmonary embolism in obesity and renal impairment
GCE/TCE/ RCE	4. Discuss diagnosis and pharmacological treatment of heparin induced thrombocytopenia
	Pharmacological Management of Weight Loss GCE ONLY
3:00-4:00pm 1hr	Pharmacological Management of Weight Loss in Adults. Cristina Sprouse PharmD (MVA)
	1. Discuss the pharmacological management of weight loss in adults
	Recognize adverse drug reactions, contraindications for use, and safety concerns for these medications Identify the role of how non-pharmacological and surgical interventions assist in weight loss management
	Evaluate patients for achieving weight loss goals upon medication monitoring and follow-up
4:00-5:00pm 1hr	Pharmacological Management of Weight Loss in Pediatrics. Aubree Houston PharmD (NCH)
4.00-5.00pm 1m	1. Review published guidelines and current literature in the treatment of obesity in children and adolescents
	2. Discuss pharmacologic options available for the treatment of obesity
	3. Apply guidelines and pharmacotherapy options to a pediatric patient case Notice to Consultant Pharmacists – Track 1 must be completed for 12hr consultant credits.
GCE/TCE	Any courses taken in Track 2 will qualify for GENERAL CE ONLY.
	TRACK 2 - Saturday, January 20, 2024
	20-1117238 GCE/TCE as Indicated
	OnSite Attendees will have Full Breakfast at 7am and Lunch at noon
8:00-10:00am	Validating Controlled Substances. Bianca Amaya PharmD & Ngozi Okwunwanne PharmD (MVA)
2hr	1. Analyze pharmacist's responsibility and judgment in determining appropriateness of controlled substance
	2. Review the use of E-FORCSE® (Electronic-Florida Online Reporting of Controlled Substances Evaluation Program) in
	validating prescriptions
	Compare medical use of controls Understand the premise of emergency filling of controlled substances.
GCE/TCE	5. Understand the premise of partial filling controlled substances.
GCL/TCL	6. Recognize appropriate methods of delivering controlled substances.
	General CE Offerings
10:00-11:00am 1hr	Contraception: Which is the Best Option? Kiara Walcott PharmD (MVA)
	Discuss the different contraceptive methods and their advantages and disadvantages.
	2. Recommend contraceptive products based on individual characteristics.3. Formulate proper patient education for hormonal contraceptive products.
	Post-Partum Depression: A Review of Pharmacological Treatment Approaches. Sian
11:00-12:00pm 1hr	Clements PharmD (NSU)
	Define Post-Partum Depression and Etiology
GCE/TCE	2. Identify Key Signs and Symptoms
30-, . 0-	3. Review Pharmacological Treatments
12:00pm-1:00pm	Lunch & Stretch Break

1:00 – 2:00pm 1hr	Men's Health: A Cause for Concern. Tobias Abreu PharmD (MVA)
	1. Discuss common and under-represented conditions that pose a risk to men's health.
	2. Review lifestyle adjustments, considerations, and guideline directed therapy to improve men's health outcomes.
	3. Explore resources available to support men's health.
2:00 -3:00pm 1hr	Sweet New Ways to Manage Type 2 – Updates in Diabetes Treatment and Technology.
2.00 3.00pm 1m	Jeremy Espeut PharmD (BHM)
	1. Discuss guidelines for the management of type 2 diabetes
	2. Understand medical therapy for management of type 2 diabetes
	3. Identify technology used in the management of type 2 diabetes
3:00-4:00pm 1hr	Transitioning Through the Healthcare System. Mireille Mitchell PharmD (JMH)
	Review the role clinical pharmacists play in transitions of care in specialty areas Review transitions of care in national undergoing transplant suggests and in national diagnosed with LIV.
	 Discuss transitions of care in patients undergoing transplant surgery and in patients diagnosed with HIV Follow and critique the course of patients as they transition from different hospital services to the outpatient setting
	Drug Selection in the Management of Alcohol Withdrawal. Christian Grillo PharmD (NSU)
4:00-5:00pm 1hr	1. Provide an overview of the risk factors and pathophysiology of alcohol dependence, alcohol addiction, and alcohol
	withdrawal
	2. Elaborate on current treatment guidelines for drug selection in patients undergoing alcohol withdrawal in different
GCE/TCE	patient populations
GCE/TCE	3. Discuss prophylaxis, alternative agents in contraindicated patients, and patient education
	TRACK 2 - Sunday, January 21, 2024
	20-1117238 GCE/ TCE as Indicated
0	InSite Attendees will have Full Breakfast at 7am and Lunch at noon
8:00-9:00am 1hr	
8.00-9.00am im	<u>Travel Medicine Made Plane and Simple.</u> Megan Backus PharmD (BHB) 1. Describe vaccines available to travelers at risk of exposure to various pathogens
	Discuss travelers' diarrhea prevention and treatment
	Understand travel health concerns and new developments in travel medicine
9:00-10:00am 1hr	Updates on Pharmacists Vaccinating the Public. Lyreima Valentin Acevedo PharmD (WNSU)
9.00-10.00am 1m	Describe recent updates on vaccines and pharmacists' immunization authority in Florida
	2. Determine immunization patient eligibility in adults.
	3. Identify reliable sources for pharmacists on vaccines updates.
10:00-11:00am 1hr	The Use of Monoclonal Antibodies in Ulcerative Colitis, Crohn's Disease and Autoimmune
	Gastrointestinal Disorders. Simon Donato PharmD (NCH)
	1. Describe the pathophysiology of autoimmune gastrointestinal (GI) disorders
	2. Compare the mechanism of action of monoclonal antibodies used for the treatment of autoimmune GI
	3. Assess the role of monoclonal antibodies and their place in therapy for the treatment of autoimmune GI disorders
11:00-12:00pm 1hr	You Can't Spell Healthcare Without THC: Updates in Medical Marijuana. Melanie Rovelo
	PharmD (MVA)
	Review the FDA approved cannabis products. Pleases qualifying modical conditions.
C C F /T C F	Discuss qualifying medical conditions. Review scheduling of cannabis products.
GCE/TCE 12:00pm-1:00pm	Lunch & Stretch Break
1:00 – 2:00pm 1hr	Don't Forget These – Updates in Alzheimer's Treatments. Juhi Saxena PharmD (MSMC)
2.00 2.00p 2	1. Provide an overview of Alzheimer's disease state
	Discuss current treatment guidelines for the management of Alzheimer's disease
	3. Identify new FDA approved treatment for Alzheimer's disease
2:00 -3:00pm 1hr	Moving Forward: Innovations in Healthcare Technologies. Livia DeMello Lino PharmD & Maria
2.00 0.000 2	Albornoz Caraballo PharmD (UM)
	Describe the influence of pharmacogenomics on current pharmacy practice
	2. Review tele pharmacy and its benefits on patient-centered care
2.00 4.00	3. Assess current healthcare integration technologies
3:00-4:00pm 1hr	Veterinary Medicine: What Pharmacists Need to Know. Dairene Leon PharmD (BHM)
	1. Define the role of the pharmacist in veterinary medicine.
	2. Discuss legal and regulatory issues that affect the practice of veterinary pharmacy.
1:00 5:00pm 1hr	3. Describe pharmacotherapy options for veterinary animals.
4:00-5:00pm 1hr	Simple and Clean: USP 797 and USP 800 Updates. Nicole Sunshine PharmD (MSMC)
	1. Describe the latest USP 797 and USP 800 standards and guidelines for sterile and hazardous compounding.
GCE/TCE	 Analyze the role of pharmacists in institutional adaptation of USP guidelines. Develop effective implementation strategies to meet USP standards.
, · 	

Notice to Consultant Pharmacists – Track 1 must be completed for 12hr consultant credits.

THANK YOU FOR YOUR ATTENDANCE

Two Day Education Registration (16 total credit hours).	Only interested in the Saturday Validation of Controlled Substances 2-
Includes hot breakfast & lunch. Indicate Track preference.	hour CE?
Member Nonmember	□ Pharmacist & Technician \$60
□ Pharmacist (full conf.) \$275 \$355 (Inc. Dues)	
□ Track 1 RCE (or GCE) □ Track 2 GCE only	Additional ADMINISTRATIVE FEE for VIRTUAL ATTENDEES via Zoom
□ Technician (full conf.) \$275 \$315 (Inc. Dues)	□ Pharmacist & technician \$25
□ Student \$60	
□ Resident Presenter; RPD No Charge	NOTE: Pricing of programs was based upon hotel contract and increase cost
□ Track 1 RPD □ Track 2 RPD	of food to be incurred. We have tried to minimize the financial impact on the
Daily Education Registration (8hr Saturday or 8hr Sunday)	cost of the program while attempting to provide a premier event meant to
Select the day you will attend: □ Saturday OR □ Sunday	accommodate everyone's comfort level. Administrative fee helps cover the
Member Nonmember	cost of Zoom fees and the recordkeeping required to substantiate on-line
□ Pharmacist (single day) \$200 \$280 (Inc. Dues)	attendance.
□ Technician (single day) \$200 \$240 (Inc. Dues)	
□ Student \$30	2024 calendar year dues are \$80 pharmacists; \$40 technicians
□ Resident Presenter; RPD No Charge	
Payments can be made by Zelle	The program "Handouts" will be posted on our web site for
· · · · · · · · · · · · · · · · · · ·	free download
(<u>dcpa@dcpa.us</u>); Credit Card OR	DEADLINE FOR ON SITE PROGRAM
PLEASE MAIL YOUR COMPLETED REGISTRATION FORM	
	REGISTRATION IS
	REGISTRATION IS
WITH PAYMENT TO:	
WITH PAYMENT TO: DCPA 1271 NE 97th Street, Miami Shores, FL 33138	5 PM Monday, JANUARY 15, 2024
WITH PAYMENT TO:	
WITH PAYMENT TO: DCPA 1271 NE 97 th Street, Miami Shores, FL 33138 REGISTRATION FORM	5 PM Monday, JANUARY 15, 2024
WITH PAYMENT TO: DCPA 1271 NE 97th Street, Miami Shores, FL 33138	5 PM Monday, JANUARY 15, 2024
WITH PAYMENT TO: DCPA 1271 NE 97 th Street, Miami Shores, FL 33138 REGISTRATION FORM Name:	5 PM Monday, JANUARY 15, 2024
WITH PAYMENT TO: DCPA 1271 NE 97 th Street, Miami Shores, FL 33138 REGISTRATION FORM	5 PM Monday, JANUARY 15, 2024
WITH PAYMENT TO: DCPA 1271 NE 97th Street, Miami Shores, FL 33138 REGISTRATION FORM Name: Address:	5 PM MONDAY, JANUARY 15, 2024 Deadline: Monday January 15, 2024
WITH PAYMENT TO: DCPA 1271 NE 97 th Street, Miami Shores, FL 33138 REGISTRATION FORM Name:	5 PM MONDAY, JANUARY 15, 2024 Deadline: Monday January 15, 2024
WITH PAYMENT TO: DCPA 1271 NE 97th Street, Miami Shores, FL 33138 REGISTRATION FORM Name: Address: City, State, Zip:	5 PM MONDAY, JANUARY 15, 2024 Deadline: Monday January 15, 2024
WITH PAYMENT TO: DCPA 1271 NE 97 th Street, Miami Shores, FL 33138 REGISTRATION FORM Name: Address:	5 PM MONDAY, JANUARY 15, 2024 Deadline: Monday January 15, 2024
WITH PAYMENT TO: DCPA 1271 NE 97th Street, Miami Shores, FL 33138 REGISTRATION FORM Name: Address: City, State, Zip:	5 PM MONDAY, JANUARY 15, 2024 Deadline: Monday January 15, 2024
WITH PAYMENT TO: DCPA 1271 NE 97th Street, Miami Shores, FL 33138 REGISTRATION FORM Name: Address: City, State, Zip: Email:	5 PM MONDAY, JANUARY 15, 2024 Deadline: Monday January 15, 2024

Thank you to our program sponsors:

